BNTC Benitec Biopharma Inc is a development-stage biotechnology company which focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics.
BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc. and Morgan Stanley have stakes in it.
On 2/17/2022 P. Trucchio from HC Wainwright brokerage Initiated Coverage for BNTC with a Buy rating and a price target of $10.00.
The price of the stock can easily double in my opinion.
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.